Status:
ACTIVE_NOT_RECRUITING
Improving Disease Severity
Lead Sponsor:
Wake Forest University Health Sciences
Conditions:
Psoriasis
Alopecia Areata
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Phototherapy, including ultraviolet B (UVB) and ultraviolet A (UVA) light, has been used to treat a number of dermatologic conditions. Psoriasis is one of the most common conditions treated with photo...
Detailed Description
Recent advancements in nanotechnology have led to the development of medical devices (lasers and LED devices) with unique phototherapy properties that emit radiation in the infrared wavelengths, allow...
Eligibility Criteria
Inclusion
- Adult participants ≥18 years of age
- Participants who live in the US,
- Participants who are diagnosed with mild-to-severe AA, PMLE, or psoriasis
- Participants have sufficient command of the English language
Exclusion
- Participants less than the age of 18
- Participants who do not live in the US
- Participants who are not diagnosed with mild to severe AA, PMLE, or psoriasis
- Participants without a sufficient command of the English language
- Participants with concurrent medical conditions that are at risk of confounding the study outcomes
- Participants currently using concomitant phototherapy
Key Trial Info
Start Date :
August 9 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2026
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT05391178
Start Date
August 9 2022
End Date
December 1 2026
Last Update
November 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wake Forest University Health Sciences, Dermatology
Winston-Salem, North Carolina, United States, 27157